Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 13/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435041 | 0.90 | CDK8 (0.48) | CDK8SYK | |
| SCHEMBL4889660 | 0.84 | CDK8 (0.67) | CDK8 | |
| SCHEMBL25129019 | 0.82 | CDK8 (0.47) | CDK8TDP2SYKCYP17A1 | |
| SCHEMBL25129021 | 0.82 | CDK8 (0.47) | CDK8TDP2SYKCYP17A1 | |
| SCHEMBL64988 | 0.82 | MAPK1 (0.51) | ATRCYP17A1 | |
| SCHEMBL5319331 | 0.81 | MAP2K7 (0.47) | — | |
| SCHEMBL2414378 | 0.81 | NAMPT (0.44) | CDK8ATRCYP17A1 | |
| SCHEMBL29996697 | 0.81 | CDK8 (0.46) | CDK8SYK | |
| SCHEMBL4732688 | 0.81 | CDK8 (0.46) | CDK8SYK | |
| SCHEMBL1028380 | 0.79 | CDK8 (0.43) | CDK8ATRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179114-A1 | Anti-Inflammatory Compound and Use Thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-118201943-A | Anti-inflammatory compound and application thereof | 映恩生物制药（苏州）有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023040793-A1 | ANTI-INFLAMMATORY COMPOUND AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179114-A1 | Anti-Inflammatory Compound and Use Thereof | TNF, IL1B, NFKBIA | CDK8 1347/4885TDP2 3264/4885SYK 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.